potential

Tight Glycemic Control in the ICU

...ip, which contains a hydrophilic foam that reduces potential for contamination. Plasma from the sample flows through the pad to the reagent membrane, where glucose undergoes the glucose oxidase reaction. The test strip is inserted into the meter, and results appear in approximately 30 seconds. The measureme...

Avian (Bird) Flu: Is There a Role for Rapid Tests?

...cceptable. Other drawbacks to rapid tests include potential compromises in biosafety, lesser performance early or late in the infection, and loss of isolates or surveillance information. Despite these cautionary statements, rapid (point-of-care) tests can aid early decisions on whether to initiate antivir...

Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing

...s lack of documentation may also have an affect on potential reimbursement issues. As health-care providers must consider each advantage and disadvantage to POCT, its technology continues to develop. The analyzers are getting faster, smaller, easier to use, and show the ability to perform accurate testing with...

Choosing Lab Quality Management Software

... successful managers will continue to evaluate the potential for information technology to help them achieve their efficiency objectives....

Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology

...s in EpiPen prescriptions in theUnited States: The potential role of vitamin D," can be found inthe July 2007 issue of the Journal of Allergy and ClinicalImmunology (JACI), the peer-reviewed journal of the AmericanAcademy of Allergy, Asthma and Immunology (AAAAI). Carlos A. Camargo, MD, DrPH, FAAAAI, and coll...

Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis

...investigate the oral direct thrombininhibitor as a potential treatment and prophylaxis for severalthromboembolic disease conditions. The phase 3 clinical trialprogram is expected to involve more than 27,000 patients from Asia,Australia, Europe, the Americas, and South Africa. Boehringer Ingelheim Pharmaceutic...

Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis

...ding Forward-LookingStatements" and discussions of potential risks and uncertainties inNeose's subsequent filings with the SEC. Contact Neose Technologies, Inc. A. Brian Davis Sr. Vice President and Chief Financial Officer 215-315-9000 or Barbara Krauter Manager, Corporate Communications 215-315-9004...

Positive Aggrastat Results Featured in the Journal of the American College of Cardiology

... PatientsWith Myocardial Infarction", outlines the potential benefit ofAGGRASTATR (tirofiban hydrochloride) plu...y with AGGRASTATR,patients should be monitored for potential bleeding. When bleedingcannot be controlled with pressure, infusion of AGGRASTATR andheparin should ...

Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent

...cal programhave provided valuable insight into the potential role ofmaintaining trough levels above 1 IU/dL to reduce the risk ofbreakthrough bleeding." Additionally, a poster presentation of data from ADAPT, resultsshowed that bleeding patterns in people with severe hemophiliausing standard prophylaxis thera...

Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis

... "This result impressively demonstrates the great potential ofour development candidate BF-200 ALA. Every other person above 60years of age in Germany has actinic keratosis, the incidencedoubles every 10 years. We will develop the 10 % formulationfurther for the treatment of this unusually frequent disease an...

YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial

...events (such as hypoxia and bradypnea) and has the potential tominimize certain otherwise expected adverse effe...t the competitive advantages of ourproduct and its potential as a best-in-class treatment for pain,"said David Allan, Chairman and CEO of YM BioSciences. "We are...

New Information on the Potential of Plasmin Shared at ISTH Congress

...ontinuing research and development of Plasmin as a potential newthrombolytic to treat acute clotting disorders,...ction and strong fibrinbinding properties, has the potential to provide improvements whentreating patients with acute clotting disorders," said VictorMarder, M.D...

Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy

...atients. Pixantrone has been designed toreduce the potential for these severe cardiotoxicities, as well asto po...ne in particular including, withoutlimitation, the potential failure of the final results of the RAPIDclinical study of pixantrone to have the same or similar re...

CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa

...including regadenoson, whichis being developed for potential use as a pharmacologic stressagent in myocardial p...tudies, and CVT-6883, whichis being developed as a potential treatment for cardiopulmonarydiseases. Regadenoson and CVT-6883 have not been determined by anyregul...

Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone

...le, we had been encouraged regardingthe compound's potential as an effective weight loss agent.However, due to ...candidates, ManhattanPharmaceuticals is developing potential therapeutics for large,underserved patient populations seeking superior treatments forconditions inc...

Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate

...ess in validating novel, effective products forthe potential treatment of asthma. In studies of its proprietary...This important milestone demonstrates the exciting potential ofAnticalin(R)-based products for the treatment of respiratorydisease," said Dr Andreas Hohlbaum, Di...

Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease

...anti-AtherOx, weanticipate this technology has the potential to become an importantaddition to medical care worldwide." "These findings indicate important relationships between AtherOxand the severity of cardiovascular disease," added Dr. Lopez. "Wehope to have the ability to match patients with a treatment t...

Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis

...inical studiesdesigned to investigate ACTEMRA as a potential new treatment forRA. Roche and Chugai have initiated the collaborative clinicaldevelopment program that has enrolled a total of more than 4,000patients in 41 countries including the United States and severalEuropean countries. About ACTEMRA (tociliz...

Samaritan's Alzheimer's Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimer's Disease

...that reflect management'scurrent beliefs about the potential for its drug candidates,science, and technology. However, as with any biopharmaceuticalunder development, there are significant risks and uncertainties inthe process of development and regulatory review. There are noguarantees that products will prov...

BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease

...e patients. According to BGI's study, FGF-1has the potential to reduce treatment costs of advanced CADpatients by 20% over a five-year period after treatment. Here is a link to the article:www.businessweek.com/technology/content/jul2007/tc2007075_259598.htm "It's exciting when a breakthrough treatment appear...

Protox Announces Positive Clinical Data from Prostate Cancer Study

...atasupport our heightened confidence regarding the potential ofPRX302 for the treatment of not only prostate c...o higher than Grade 1(mild). Assessment of potential therapeutic activity was determined bymeasuring PSA levels throughout the study and conductingprost...

Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology

...ookingstatements frequently are used in discussing potential productapplications, potential collaborations, product developmentactivities, clinical studies, regulatory submissions and approval...

Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

...oductsin disease areas with significant commercial potential and unmetmedical needs. Inspire employs a U.S. sales force for the promotionof AzaSite(TM) (azithromycin ophthalmic solution) 1% for bacterialconjunctivitis, Elestat(R) (epinastine HCl ophthalmic solution)0.05% for allergic conjunctivitis and Restasi...

Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

...any to finance research anddevelopment activities, potential challenges to or violations ofpatents, uncertainties regarding the outcome of clinical trials,the company's ability to secure necessary approvals from regulatoryagencies, dependence upon third-party vendors, and other risksdiscussed in the company's ...

New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility

...formation in venous andarterial vessels to prevent potential acute or chroniccomplications of venous or arterial thrombosis. As with allanticoagulants, the most frequently reported side effect withLovenox(R) is bleeding. Clinical indications for Lovenox(R) mayvary from one country to another. About sanofi-ave...

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

...veniently in the hospital and homesettings has the potential to improve upon current therapies andhelp to treat the significant number of under- and un-treatedpatients at risk for life-threatening thrombotic events." The trade name of rivaroxaban is expected to be Xarelto(R),pending health authority approval....

Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference

...m Cougar's drugdevelopment programs, including the potential advantages of CB7630and its potential for use in the treatment of CRPC and in secondline hormone and chemotherapy treatment settings. Such...

TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment

...y of the ViaDerm-hPTH (1-34) product,bringing this potential product to an advanced clinical stagebefore seeking a partner to take it to market," Dr. Heffetzadded. About Osteoporosis hPTH (1-34) is currently the only osteoporosis drug to possessanabolic properties. According to the National OsteoporosisFound...

Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings

... uncertainties as tothe utility and market for our potential products; uncertaintiesassociated with pre-clinical and clinical trials of our productcandidates. More information about those risks and uncertainties iscontained in the Company's most recent quarterly or annual reportand in the Company's other repor...

Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea

...nting results that alter our expectationsabout the potential for commercializing tolevamer in the nearfuture," ...ge the intestine. A non-antibioticapproach has the potential to treat CDAD and reduce the number ofdisease recurrences, resulting in improved quality of life for...

Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis

...'s clinicaldevelopment of its drug candidates, the potential benefits of theCompany's drug candidates and the size of the potential market forthe Company's products. Such statements are based on management'scurrent expectations, but...

New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV

...reported in patientstreated with ARV therapy. The potential for HIV-cross-resistance among protease inhibitors...egnancy only if the potentialbenefit justifies the potential risk. There are no adequate andwell-controlled studies in pregnant women. The effects of PREZISTAon ...

DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC

...d opportunities, includingstatements regarding the potential use of orBec® for thetreatment of gastrointestinal GVHD and the prospects for regulatoryfilings for orBec®. Where possible, DOR has tried to identifythese forward-looking statements by using words such as"anticipates," "believes," "intends," ...

BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease

...e patients. According to BGI's study, FGF-1has the potential to reduce treatment costs of advanced CADpatients by 20% over a five-year period after treatment. Here is a link to the article:www.businessweek.com/technology/content/jul2007/tc2007075_259598.htm "It's exciting when a breakthrough treatment appear...

Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine

...rmation aboutthis investigational compound and its potential in patients withadvanced breast cancer that is no ...hor development of cancer cells. Epothilones are a potential newclass of antineoplastic (or chemotherapy) agents. For informationon ixabepilone clinical trials, ...

Peer Reviewed Journal Article Indicates Repros' Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer

...July 1, 2007 issue of Oncology Reportsindicating a potential for a new approach to the treatment ofbreast cance...tins such as Proellex have beenpostulated to be of potential benefit in the treatment of breastcancer. Unfortunately, most of the drugs in the class havesignific...

Rosetta Genomics and Weizmann Institute Scientists Identify Role of microRNA in Cancer Suppression

...nceand Rosetta Genomics . The findings suggest the potential for aspecific, single microRNA (miR-34a) to be use...umor suppression.Moreover, the results suggest the potential that a syntheticmiR-34a-like agent could be used as a cancer therapy. We stronglybelieve this resear...

Avexa's Apricitabine Clinical Trial Update

...opment remains on schedule and isdemonstrating its potential as a safe and effective treatment forHIV," stated Dr. Julian Chick, CEO of Avexa. Avexa Limited is a Melbourne-based biotechnology company with afocus on research and development of drugs for the treatment ofinfectious diseases, in particular diseas...

Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease

... to discover the functions ofsecreted proteins and potential antibody targets identified throughGenentech's Sec... to sixtargets. Genentech retains an option on the potential developmentand commercialization of the biotherapeutic drugs that Lexicondevelops from the collabora...

Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee

...leratedPain Relief Adlea is long-acting, with the potential to provide pain relieffor weeks or months after just a single localized treatment. It isa non-opioid TRPV1 agonist with a unique mechanism of action thatprovides a long-lasting, localized effect on C-fibers and blocksthe transmission of aching, throb...

Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections

...al drug compound knownas CSA-13 shows promise as a potential therapy to treat multidrugresistant Pseudomonas ae...l for therapeutic use. "This new compound has the potential to be a significant advancein the treatment of patients with cystic fibrosis and other lunginfection...

Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival

...nia and tumor lysis syndrome. Women ofchildbearing potential should avoid becoming pregnant while beingtreated with VELCADE. Cases of severe sensory and motor peripheralneuropathy have been reported. The long-term outcome of peripheralneuropathy has not been studied in mantle cell lymphoma. Acutedevelopment or...

Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme

...disorder. The papersupports the view that there is potential to use COMT inhibitors inameliorating their cognit...: "CeNeS is excitedabout its discovery programme's potential to deliver improved drugsfor the treatment of Parkinson's disease. Academic data continuesto suggest...

DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC

...d opportunities, includingstatements regarding the potential use of orBec® for thetreatment of gastrointestinal GVHD and the prospects for regulatoryfilings for orBec®. Where possible, DOR has tried to identifythese forward-looking statements by using words such as"anticipates," "believes," "intends," ...

Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis

... Today’s results oncemore also highlight the potential of Traditional Chinese Medicineto provide a reservoir for innovative new drugs for the globalpharmaceutical market.” Ends Enquiries Chi-Med Christian Hogg, CEO Telephone: +852 2121 8200 Citigate Dewe Rogerson Anthony Carlisle Yvonne Ale...

Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

...lopment of ispinesib with a focused approachto the potential treatment of breast cancer with ispinesib.? Clini...additional Phase II clinical trials,evaluating the potential efficacy of ispinesib in an array ofdifferent tumor types. Enrollment has been closed for all ofthe...

European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGene's Cancer-Killing Virus in Press Conference

...er congress, this emphasizes the innovationand the potential of this approach to fight cancer." Journalists interested in joining the press conference pleasecontact <a target="_blank" href="mailto:media@esmo.org">media@esmo.org This press release contains forward-looking statements thatinvolve risks...

Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstrom's Macroglobulinemia

...cals,commented "We are very enthusiastic about the potential ofperifosine in the treatment of multiple myeloma and Waldenstrom'smacroglobulinemia and the prospects of using perifosine to improveupon the current care for these patients." In addition to the clinical posters, three pre-clinical posterswere prese...

Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma

...nia and tumor lysis syndrome. Women ofchildbearing potential should avoid becoming pregnant while beingtreated with VELCADE. Cases of severe sensory and motor peripheralneuropathy have been reported. The long-term outcome of peripheralneuropathy has not been studied in mantle cell lymphoma. Acutedevelopment or...

Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients

...nia and tumor lysis syndrome. Women ofchildbearing potential should avoid becoming pregnant while beingtreated with VELCADE. Cases of severe sensory and motor peripheralneuropathy have been reported. The long-term outcome of peripheralneuropathy has not been studied in mantle cell lymphoma. Acutedevelopment or...

Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop

...e-seeking phosphonate (EDTMP) with the therapeutic potential ofradiation (samarium Sm-153). Skeletal invasion by prostate, breast,multiple myeloma, and other cancers often creates an imbalancebetween the normal process of bone destruction and formation.QUADRAMET selectively targets such sites of imbalance, the...

Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension

...ledge in renin inhibition which we believe has the potential tobe the next gold standard for the treatment of d...re is a considerable unmet medicalneed. The latest potential therapeutic agents for hypertension are renininhibitors. Renin is an enzyme produced in the kidneys ...

A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients

...07. "These data are very encouraging and show the potential of aregenerative therapy in diabetes," said Sherwy...in patients six monthpost-treatment, highlight the potential that E1-I.N.T.(TM) therapycould provide patients significant clinical benefit in excess of 6months. ...

Gentium's Defibrotide Seen as Active in Multiple Myeloma

...ailable agent in combination withchemotherapy as a potential treatment for multiple myeloma." About Gentium Gentium, S.p.A., located in Como, Italy, is a biopharmaceuticalcompany focused on the research, development and manufacture ofdrugs to treat and prevent a variety of vascular diseases andconditions rel...

Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company

...of the PhaseIII clinical trials for CellCept(R), a potential treatment forlupus kidney disease being tested by Aspreva PharmaceuticalCompany. Development of new treatments for lupus patients iscritical because many of the drugs currently used to treat thedisease are toxic and can cause serious medical complica...

Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice

...aid David McWilliams, chiefexecutive officer. "The potential use of adult MDSCs for thedevelopment of functional MDIs maybe a viable alternative to thedevelopment of islet cells derived from embryonic stem cells." About Opexa Therapeutics Opexa Therapeutics develops and commercializes cell therapies totreat ...

Aspreva and Roche Announce Preliminary Results for Phase III Study Evaluating CellCept in Lupus Nephritis

...d.Additional analyses are ongoing to determine the potential for aregulatory submission and Aspreva plans to pr...ept should not be used in pregnant womenunless the potential benefit justifies the potential risk to thefetus. Women of childbearing potential should have a nega...

In Vitro and In Vivo Data Show Alfacell's Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells

...firmed in animals. "The data speak to the broad potential application for ONCONASEin various types of cancer...any to finance research anddevelopment activities, potential challenges to or violations ofpatents, uncertainties regarding the outcome of clinical trials,the co...

CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS

...ense that will be incurredin developing any of the potential commercial applications forarimoclomol and the potential need for additional capital to fundthe development of arimoclomol, as well as other risks oruncertai...

Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer

...multi-center Phase 2clinical trials supporting the potential use of Xcytrin(R)(motexafin gadolinium) Injection,...h at ASCO, these data continue to supportXcytrin's potential role in this underserved cancer and furtherinform the design of our pivotal Phase 3 trial in this in...